share_log

Bruker Corp | 10-Q: Q3 2024 Earnings Report

Bruker Corp | 10-Q: Q3 2024 Earnings Report

布鲁克 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/08 11:40

Moomoo AI 已提取核心信息

Bruker Corporation reported Q3 2024 revenue of $864.4 million, a 16.4% increase from $742.8 million in Q3 2023, driven by 12.5% growth from acquisitions and 0.7% favorable foreign exchange impact. Organic revenue grew 3.1% year-over-year, reflecting strong demand for scientific instruments and life science solutions.Gross profit margin declined to 48.4% from 51.5% in Q3 2023, impacted by product mix and acquisition-related costs. Operating income decreased 45.3% to $68.1 million, while net income attributable to Bruker fell 53.6% to $40.9 million, primarily due to higher interest expenses of $11.6 million from increased borrowings and $4.4 million in minority investment impairments.The company completed several strategic acquisitions including ELITech, NanoString and Chemspeed, expanding its capabilities in molecular diagnostics and lab automation. Geographic revenue growth was strong across regions, with North America up 14.8%, Asia Pacific up 14.4%, and Europe up 15.0%. The company maintained its financial covenants compliance with total debt of $2.3 billion as of September 30, 2024.
Bruker Corporation reported Q3 2024 revenue of $864.4 million, a 16.4% increase from $742.8 million in Q3 2023, driven by 12.5% growth from acquisitions and 0.7% favorable foreign exchange impact. Organic revenue grew 3.1% year-over-year, reflecting strong demand for scientific instruments and life science solutions.Gross profit margin declined to 48.4% from 51.5% in Q3 2023, impacted by product mix and acquisition-related costs. Operating income decreased 45.3% to $68.1 million, while net income attributable to Bruker fell 53.6% to $40.9 million, primarily due to higher interest expenses of $11.6 million from increased borrowings and $4.4 million in minority investment impairments.The company completed several strategic acquisitions including ELITech, NanoString and Chemspeed, expanding its capabilities in molecular diagnostics and lab automation. Geographic revenue growth was strong across regions, with North America up 14.8%, Asia Pacific up 14.4%, and Europe up 15.0%. The company maintained its financial covenants compliance with total debt of $2.3 billion as of September 30, 2024.
布鲁克公司报告2024年第三季度营收为$86440万，同比增长16.4%，相比2023年第三季度的$74280万，这主要得益于收购带来的12.5%的增长和0.7%的有利汇率期货影响。自然营收同比增长3.1%，反映出对科学仪器和生命科学解决方案的强劲需求。毛利润率从2023年第三季度的51.5%下降至48.4%，受产品组合和收购相关成本的影响。营业收入下降45.3%至$6810万，而归属于布鲁克的净利润则下降53.6%至$4090万，主要由于利息支出增加至$1160万以及$440万的少数股权投资减值。公司完成了包括ELITech、NanoString和Chemspeed在内的多项战略收购，增强了其在分子诊断和实验室自动化领域的能力。各地区的营业收入增长强劲，北美增长14.8%，亚太地区增长14.4%，欧洲增长15.0%。截至2024年9月30日，公司保持其财务契约合规，总债务为$23亿。
布鲁克公司报告2024年第三季度营收为$86440万，同比增长16.4%，相比2023年第三季度的$74280万，这主要得益于收购带来的12.5%的增长和0.7%的有利汇率期货影响。自然营收同比增长3.1%，反映出对科学仪器和生命科学解决方案的强劲需求。毛利润率从2023年第三季度的51.5%下降至48.4%，受产品组合和收购相关成本的影响。营业收入下降45.3%至$6810万，而归属于布鲁克的净利润则下降53.6%至$4090万，主要由于利息支出增加至$1160万以及$440万的少数股权投资减值。公司完成了包括ELITech、NanoString和Chemspeed在内的多项战略收购，增强了其在分子诊断和实验室自动化领域的能力。各地区的营业收入增长强劲，北美增长14.8%，亚太地区增长14.4%，欧洲增长15.0%。截至2024年9月30日，公司保持其财务契约合规，总债务为$23亿。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！